Gene-editing therapy demonstrates sustained LDL cholesterol reduction in one-year clinical trial

A small-scale clinical study indicates that a single-dose gene-editing treatment successfully lowered LDL cholesterol levels, with effects persisting for at least 12 months. While the long-term safety profile and scalability remain uncertain, the results represent a potential shift in the management of chronic cardiovascular disease.